

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PAR PHARMACEUTICAL, INC.,	)	
PAR STERILE PRODUCTS, LLC, and	)	
ENDO PAR INNOVATION	)	
COMPANY, LLC,	)	
	)	C.A. No. 18-823-CFC-JLH
Plaintiffs,	)	
	)	
v.	)	<b><u>FILED UNDER SEAL</u></b>
	)	
EAGLE PHARMACEUTICALS INC.,	)	
	)	
Defendant.	)	

**APPENDIX OF DOCUMENTS CITED IN  
BRADLEY AND JAROSZ DECLARATIONS IN SUPPORT OF PAR'S  
MOTION FOR A PRELIMINARY INJUNCTION PENDING APPEAL**

Dated: December 16, 2021

Brian E. Farnan (Bar No. 4089)  
Michael J. Farnan (Bar No. 5165)  
FARNAN LLP  
919 N. Market St., 12th Floor  
Wilmington, DE 19801  
Telephone : (302) 777-0300  
Fax : (302) 777-0301  
bfarnan@farnanlaw.com  
mfarnan@farnanlaw.com

Martin J. Black (admitted *pro hac vice*)  
Sharon K. Gagliardi (admitted *pro hac vice*)  
Brian M. Goldberg (admitted *pro hac vice*)  
DECHERT LLP  
Cira Centre  
2929 Arch Street  
Philadelphia, PA 19104  
Tel: (215) 994-4000  
martin.black@dechert.com

sharon.gagliardi@dechert.com  
brian.goldberg@dechert.com

Robert D. Rhoad (admitted *pro hac vice*)  
DECHERT LLP  
502 Carnegie Center  
Suite #104  
Princeton, NJ 08540  
Tel: (609) 955-3200  
robert.rhoad@dechert.com

Jonathan Loeb (admitted *pro hac vice*)  
Dechert LLP  
3000 El Camino Real  
Suite 650  
Palo Alto, CA 94306  
Tel: (650) 813-4995  
jonathan.loeb@dechert.com

Blake B. Greene (admitted *pro hac vice*)  
DECHERT LLP  
300 W. 6th Street, Suite 2010  
Austin, TX 78701  
Tel: (512) 394-3000  
blake.greene@dechert.com

*Attorneys for Plaintiffs Par Pharmaceutical,  
Inc., Par Sterile Products, LLC, and Endo  
Par Innovation Company, LLC*

## Table of Contents

[illegible]

<b>Description</b>	<b><u>Page No.</u></b>
“Drugs@FDA: FDA-Approved Drugs,” FDA, <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=212593">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=212593</a> (viewed December 6, 2020).	p. 40
“Drugs@FDA: FDA-Approved Drugs,” FDA, <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=204485">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=204485</a> (viewed December 7, 2021).	p. 50
American Regent Generic Vasopressin Label	p. 55
“Approval Package for: Application Number: 204485Orig1s003,” Center for Drug Evaluation and Research, <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204485Orig1s003.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204485Orig1s003.pdf</a>	p. 62
“NDA 204485,” Department of Health and Human Services, <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204485Orig1s000ltr.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204485Orig1s000ltr.pdf</a> .	p. 91
“NDA 212593,” U.S. Food and Drug Administration, <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212593Orig1s000ltr.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212593Orig1s000ltr.pdf</a> .	p. 95
“Prescribing Information,” FDA, <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf</a> ;	p. 99
“Statement on FDA’s new report regarding root causes and potential solutions to drug shortages,” FDA, <a href="https://www.fda.gov/news-events/press-announcements/statement-fdas-new-report-regarding-root-causes-and-potential-solutions-drug-shortages">https://www.fda.gov/news-events/press-announcements/statement-fdas-new-report-regarding-root-causes-and-potential-solutions-drug-shortages</a> (viewed November 23, 2021).	p. 227
<b>Financials</b>	<b>Vol. 3-1</b>
Eagle Pharmaceuticals, Inc. SEC Form 10-K for the fiscal year ended December 31, 2018.	p. 1
Eagle Pharmaceuticals, Inc. SEC Form 10-K for the fiscal year ended December 31, 2019.	p. 210
Eagle Pharmaceuticals, Inc. SEC Form 10-K for the fiscal year ended December 31, 2020.	p. 402
Endo International, PLC SEC Form 10-Q for the quarterly period ended June 30, 2021.	p. 629
Endo International, PLC SEC Form 10-Q for the quarterly period ended September 30, 2021.	p. 681

<b>Description</b>	<b><u>Page No.</u></b>
Endo International, PLC SEC Form 10-K for the fiscal year ended December 31, 2017.	p. 732
Endo International, PLC SEC Form 10-K for the fiscal year ended December 31, 2018.	p. 920
<b>Financials</b>	<b>Vol. 3-2</b>
Endo International, PLC SEC Form 10-K for the fiscal year ended December 31, 2019.	p. 1
Endo International, PLC SEC Form 10-K for the fiscal year ended December 31, 2020.	p. 230
Endo International, PLC SEC Form 10-Q for the quarterly period ended June 30, 2021.	p. 451
Endo International, PLC SEC Form 10-Q for the quarterly period ended March 31, 2021.	p. 529
Endo International, PLC SEC Form 10-Q for the quarterly period ended September 30, 2020.	p. 609
Endo International, PLC SEC Form 10-Q for the quarterly period ended September 30, 2021.	p. 691
Par Pharmaceutical Holdings, Inc., SEC Form S-1, March 12, 2015.	p. 752
<b>Patents</b>	<b>Vol. 4</b>
U.S. Patent No. 9,744,209	p. 1
U.S. Patent No. 9,750,785	p. 84
<b>Publications</b>	<b>Vol. 5-1</b>
Aitken, Murray L., <i>et al.</i> , “The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity,” <i>National Bureau of Economic Research</i> , Working Paper No. 19487 (2013): 1-37.	p. 1
Ames, Daniel R., and Malia Mason, “Tandem Anchoring: Informational and Politeness Effects of Range Offers in Social Exchange,” <i>Journal of Personality and Social Psychology</i> , Vol. 108, No. 2 (2015): 254-274	p. 40
Brealey, Richard A., Stewart C. Meyers, and Franklin Allen, <i>Principles of Corporate Finance</i> (2011), Tenth Edition, McGraw-Hill/Irwin.	p. 61
Busby, Daniel, and Steve Daddeo, “Eagle Pharmaceuticals,” RBC Capital Markets (August 9, 2021).	p. 1030

Description	<u>Page No.</u>
Caves, Richard, <i>et al.</i> , “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry,” <i>Brookings Papers on Economic Activity: Microeconomics</i> , 22 (1991): 1-66.	p. 1039
Conrad, Ryan, and Randall Lutter, “Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices,” U.S. Food & Drug Administration Report (December 2019): 1-9.	p. 1106
Cook, Anna, “How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry,” The Congress of the United States Congressional Budget Office Study (July 1998): 62-63.	p. 1115
Danzon, Patricia M., and Michael F. Furukawa, “Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician Driven Markets,” <i>National Bureau of Economic Research</i> , Working Paper No. 17226 (2011): 1-44.	p. 1206
Danzon, Patricia M., and Michael F. Furukawa, “Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician Driven Markets,” <i>National Bureau of Economic Research</i> , Working Paper No. 17226 (2011): 1-44.	p. 1250
Gourville, John T., and Jonathan J. Koeler, “Downsizing Price Increases: A Greater Sensitivity to Price than Quantity in Consumer Markets,” <i>Harvard Business School Marketing Research Papers</i> (June 2004).	p. 1266
Grabowski, Henry G., “Patents and New Product Development in the Pharmaceuticals and Biotechnology Industries,” in <i>Science and Cents: The Economics of Biotechnology</i> (2002), pp. 87-104, edited by John Duca and Mine K. Yucel (Federal Reserve Bank of Dallas).	p. 1307
Grabowski, Henry, “Are the Economics of Pharmaceutical Research and Development Changing? Productivity, Patents and Political Pressures,” <i>Pharmacoeconomics</i> , Vol. 22, Suppl. 2 (2004): 15-24.	p. 1337
Grabowski, Henry G., and John M. Vernon, “Effective Patent Life in Pharmaceuticals,” <i>Int. J. Technology Management</i> , Vol. 19, Nos. 1/2 (2000): 98-120.	p. 1347
Grabowski, Henry G., and John Vernon, “Brand Loyalty, Entry, and Price Competition in Pharmaceuticals After the 1984 Drug Act,” <i>The Journal of Law &amp; Economics</i> , Vol. 35, No. 2 (1992): 331-350.	p. 1370

<b>Description</b>	<b><u>Page No.</u></b>
Grabowski, Henry, <i>et al.</i> , “Updated Trends in US Brand-Name and Generic Drug Competition,” <i>Journal of Medical Economics</i> , Vol. 19, No. 9 (2016): 836-844.	p. 1391
Harrington, Scott E., “Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms,” in <i>The Oxford Handbook of the Economics of the Biopharmaceutical Industry</i> (2012).	p. 1400
Higgins, Matthew J., and Stuart J. H. Graham, “Balancing Innovation and Access: Patent Challenges Tip the Scales,” <i>Science</i> , Vol. 326, No. 5951 (2009): 370-71.	p. 1442
Hollenberg, Steven, “Vasoactive Drugs in Circulatory Shock,” <i>American Journal of Respiratory Critical Care Medicine</i> , Vol. 183 (2011): 847-855.	p. 1444
J.P. Morgan, “Endo International PLC – 3Q Takeaways: Significant Beat on Vasostrict and Gx Launches but Longer-term Uncertainties Remain,” (November 5, 2021).	p. 1453
Kahneman, Daniel, “Reference Points, Anchors, Norms, and Mixed Feelings,” <i>Organizational Behavior and Human Decision Processes</i> , Vol. 51 (1992): 296-312.	p. 1464
Kahneman, Daniel, and Amos Tversky, “Prospect Theory: An Analysis of Decision Under Risk,” <i>Econometrica</i> , Vol. 47 (1979): 263-292	p. 1481
Kahneman, Daniel, and Amos Tversky, “Judgment under Uncertainty: Heuristics and Biases,” <i>Science</i> , Vol. 185 (1974): 1124-1131.	p. 1511
<b>Publications</b>	<b>Vol 5-2</b>
Kahneman, Daniel, Jack Knetsch, and Richard Thaler, “Anomalies: The Endowment Effect, Loss Aversion, and Status Quo Bias,” <i>Journal of Economic Perspectives</i> , Vol. 5, No. 1 (1991): 193-206.	p. 1
Kalwani, Manohar U., <i>et al.</i> , “A Price Expectations Model of Customer Brand Choice,” <i>Journal of Marketing Research</i> , Vol. 27 (1990): 251-262.	p. 133
Knowles, Sherry M., “Fixing the Legal Framework for Pharmaceutical Research,” <i>Science</i> , Vol. 327, No. 5969 (2010): 1083-84.	p. 146
Lahiry, Sandeep, Sayanta Thakur, and Dwaipayan S. Chakraborty, “Advances in Vasodilatory Shock: A Concise Review,” <i>Indian Journal of Critical Care Medicine</i> , Vol. 23, No. 10 (2019): 475-480, available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842826/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842826/</a> .	p. 148



<b>Description</b>	<b><u>Page No.</u></b>
Lehman, Bruce, “The Pharmaceutical Industry and the Patent System,” <i>International Intellectual Property Institute</i> (2003): 1-14.	p. 161
Mankiw, N. G., <i>Principles of Economics</i> (2011), Sixth Edition, South-Western Cengage Learning.	p. 175
Moody’s Investor Service, “Rating Action: Moody’s Downgrades Endo’s CFR to Caa1,” (August 25, 2021).	p. 1065
Poston, Jason T., Bhakti K. Patel, and Andrew M. Davis, “Management of Critically Ill Adults with Covid-19,” <i>Jama</i> , Vol. 323, No. 18 (2020): 1839-1841.	p. 1072
Regan, Tracy L., “Generic Entry, Price Competition, and Market Segmentation in the Prescription Drug Market,” <i>International Journal of Industrial Organization</i> , Vol 26. (2008): 930-948.	p. 1075
Rhodes, Andrew, <i>et al.</i> , “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” <i>Critical Care Medicine</i> , Vol. 45, No. 3 (2017): 486-552.	p. 1094
S&P Global Ratings, “Endo International PLC Downgraded to ‘CCC+’ from ‘B-’ on Vasostrict Trial Outcome; Outlook Negative,” (September 2, 2021).	p. 1161
Saha, Atanu, <i>et al.</i> , “Generic Competition in the US Pharmaceutical Industry,” <i>International Journal of the Economics of Business</i> , Vol. 13, No. 1 (2006): 15-38.	p. 1169
Saha, Atanu, and Heather Roberts, “Pharmaceutical industry's changing market dynamics,” <i>International Journal of the Economics of Business</i> , Vol. 27, No. 2 (2020): 159-175.	p. 1193
Secomb, Timothy, “Hemodynamics,” <i>Comprehensive Physiology</i> , Vol. 6, No. 2 (2016): 975-1003.	p. 1211
Silver, Richard, “A Wall Street Perspective on Generics,” 2007 EGA Annual Conference, Lehman Brothers (June 14-16, 2007).	p. 1279
Treschan, Tanja, and Jurgen Peters, “The Vasopressin System,” <i>Anesthesiology</i> , Vol. 105, No. 3 (2006): 599-612.	p. 1319
United States Federal Trade Commission, “To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy,” (2003), available at <a href="https://www.ftc.gov/sites/default/files/documents/reports/promote-innovation-proper-balance-competition-and-patent-law-and-policy/innovationrpt.pdf">https://www.ftc.gov/sites/default/files/documents/reports/promote-innovation-proper-balance-competition-and-patent-law-and-policy/innovationrpt.pdf</a> .	p. 1333







<b>Description</b>	<b><u>Page No.</u></b>
<b>Websites</b>	<b>Vol. 6</b>
“Postcardiotomy Cardiogenic Shock,” ABIOMED, <a href="https://www.abiomed.com/disease-states/postcardiotomy-cardiogenic-shock">https://www.abiomed.com/disease-states/postcardiotomy-cardiogenic-shock</a> (viewed December 6, 2020).	p. 1
“Eagle Pharmaceuticals Reports Second Quarter 2021 Results,” Business Wire, <a href="https://www.businesswire.com/news/home/20210809005147/en/Eagle-Pharmaceuticals-Reports-Second-Quarter-2021-Results">https://www.businesswire.com/news/home/20210809005147/en/Eagle-Pharmaceuticals-Reports-Second-Quarter-2021-Results</a> (viewed November 23, 2021).	p. 7
“Eagle Pharmaceuticals Wins Vasopressin Patent Trial,” Business Wire, <a href="https://www.businesswire.com/news/home/20210831005804/en/Eagle-Pharmaceuticals-Wins-Vasopressin-Patent-Trial">https://www.businesswire.com/news/home/20210831005804/en/Eagle-Pharmaceuticals-Wins-Vasopressin-Patent-Trial</a> (viewed November 23, 2021).	p. 21
“What is 505(b)(2)?,” Camargo, <a href="https://camargopharma.com/resources/what-is-505b2/">https://camargopharma.com/resources/what-is-505b2/</a> (viewed September 27, 2021).	p. 23
“How is Sepsis Diagnosed and Treated?” CDC, <a href="https://www.cdc.gov/sepsis/diagnosis/index.html">https://www.cdc.gov/sepsis/diagnosis/index.html</a> (viewed December 3, 2020).	p. 36
“Market capitalization of Eagle Pharmaceuticals (EGRX),” CompaniesMarketCap.com, <a href="https://companiesmarketcap.com/eagle-pharmaceuticals/marketcap/">https://companiesmarketcap.com/eagle-pharmaceuticals/marketcap/</a> (viewed December 5, 2021).	p. 37
“Market capitalization of Endo International (ENDP),” CompaniesMarketCap.com, <a href="https://companiesmarketcap.com/endo-international/marketcap/">https://companiesmarketcap.com/endo-international/marketcap/</a> (viewed December 5, 2021).	p. 41
“Par Pharmaceutical, Inc.,” Dun & Bradstreet, <a href="https://www.dnb.com/business-directory/company-profiles.par_pharmaceutical_inc.a5e909cadd10c29d3f33a26e357e3095.html">https://www.dnb.com/business-directory/company-profiles.par_pharmaceutical_inc.a5e909cadd10c29d3f33a26e357e3095.html</a> (viewed December 2, 2020).	p. 45
“Dexmedetomidine,” Drugs.com, <a href="https://www.drugs.com/mtm/dexmedetomidine.html">https://www.drugs.com/mtm/dexmedetomidine.html</a> (viewed November 23, 2021).	p. 51
“Distributive Shock,” Medscape, <a href="https://emedicine.medscape.com/article/168689-overview#showall">https://emedicine.medscape.com/article/168689-overview#showall</a> (viewed December 3, 2020).	p. 56

<b>Description</b>	<b><u>Page No.</u></b>
“What Are Vasopressors?” Everyday Health, Inc., <a href="https://www.everydayhealth.com/vasopressors/guide/">https://www.everydayhealth.com/vasopressors/guide/</a> (viewed December 3, 2020).	p.61
“Amneal Pharmaceuticals, inc (AMRX) Q2 2021 Earnings Call Transcript,” The Motley Fool, <a href="https://www.fool.com/earnings/call-transcripts/2021/08/09/amneal-pharmaceuticals-inc-amrx-q2-2021-earnings-c/">https://www.fool.com/earnings/call-transcripts/2021/08/09/amneal-pharmaceuticals-inc-amrx-q2-2021-earnings-c/</a> (viewed September 27, 2021).	p. 70
“Par Pharmaceutical Companies, Inc. History,” Funding Universe, <a href="http://www.fundinguniverse.com/company-histories/par-pharmaceutical-companies-inc-history/">http://www.fundinguniverse.com/company-histories/par-pharmaceutical-companies-inc-history/</a> (viewed December 2, 2020).	p. 89
“Medical Crash Cart Medications Auto-Replenishment Request for Quote,” HealthFirst, <a href="https://www.healthfirst.com/medical/crashcart-signup-copy-2/">https://www.healthfirst.com/medical/crashcart-signup-copy-2/</a> (viewed November 23, 2021).	p. 94
“Distributive Shock,” Health Jade, <a href="https://healthjade.net/distributive-shock/">https://healthjade.net/distributive-shock/</a> (viewed December 6, 2021).	p. 101
“Is Vasodilation Good?” Healthline Media UK Ltd, <a href="https://www.healthline.com/health/vasodilation">https://www.healthline.com/health/vasodilation</a> (viewed December 3, 2020).	p. 127
“Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin,” Eagle Pharmaceuticals, <a href="https://investor.eagleus.com/press-releases/news-details/2021/Eagle-Pharmaceuticals-Announces-FDA-Maintains-Prioritization-of-ANDA-for-Vasopressin/default.aspx">https://investor.eagleus.com/press-releases/news-details/2021/Eagle-Pharmaceuticals-Announces-FDA-Maintains-Prioritization-of-ANDA-for-Vasopressin/default.aspx</a> (viewed December 4, 2021).	p. 162
“Eagle Pharmaceuticals Reports Second Quarter 2021 Results,” Eagle Pharmaceuticals, <a href="https://investor.eagleus.com/press-releases/news-details/2021/Eagle-Pharmaceuticals-Reports-Second-Quarter-2021-Results/default.aspx">https://investor.eagleus.com/press-releases/news-details/2021/Eagle-Pharmaceuticals-Reports-Second-Quarter-2021-Results/default.aspx</a> (viewed November 23, 2021).	p. 165
“Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader,” Endo, <a href="https://investor.endo.com/news-releases/news-release-details/endo-acquire-par-pharmaceutical-strategically-expanding-generics">https://investor.endo.com/news-releases/news-release-details/endo-acquire-par-pharmaceutical-strategically-expanding-generics</a> (viewed December 2, 2020).	p. 177
“Endo Announces Issuance of Vasostrict Patent,” Endo, <a href="https://investor.endo.com/news-releases/news-release-details/endo-announces-issuance-vasostrict-tr-patent">https://investor.endo.com/news-releases/news-release-details/endo-announces-issuance-vasostrict-tr-patent</a> (viewed November 23, 2021).	p. 184
“Guy Donatiello,” LinkedIn, <a href="https://www.linkedin.com/in/guy-donatiello-b278252/">https://www.linkedin.com/in/guy-donatiello-b278252/</a> (viewed December 5, 2021).	p. 187

<b>Description</b>	<b><u>Page No.</u></b>
“Rich Valiga,” LinkedIn, <a href="https://www.linkedin.com/in/rich-valiga-a564846/">https://www.linkedin.com/in/rich-valiga-a564846/</a> (viewed December 5, 2021).	p. 194
“Lawrence Brown,” LinkedIn, <a href="https://www.linkedin.com/in/lawrence-brown-3aa6329/">https://www.linkedin.com/in/lawrence-brown-3aa6329/</a> (viewed December 7, 2021).	p. 200
“What to Know About Vasodilation,” Medical News Today, <a href="https://www.medicalnewstoday.com/articles/327402">https://www.medicalnewstoday.com/articles/327402</a> (viewed December 3, 2020).	p. 207
“Palonosetron Injection,” MedlinePlus, <a href="https://medlineplus.gov/druginfo/meds/a610002.html">https://medlineplus.gov/druginfo/meds/a610002.html</a> (viewed December 6, 2021).	p. 228
“Septic Shock Treatment and Management,” Medscape, <a href="https://emedicine.medscape.com/article/168402-treatment">https://emedicine.medscape.com/article/168402-treatment</a> (viewed September 14, 2021).	p. 232
“Distributive Shock,” StatPearls Publishing LLC, <a href="https://www.ncbi.nlm.nih.gov/books/NBK470316/">https://www.ncbi.nlm.nih.gov/books/NBK470316/</a> (viewed November 24, 2021).	p. 233
“Septic Shock,” NHS, <a href="https://www.nhsinform.scot/illnesses-and-conditions/blood-and-lymph/septic-shock">https://www.nhsinform.scot/illnesses-and-conditions/blood-and-lymph/septic-shock</a> (viewed December 3, 2020).	p. 242
“Senators Condemn Big Price Increases for Drugs,” The New York Times, <a href="http://www.nytimes.com/2015/12/10/business/senators-condemn-big-price-increases-for-drugs.html">http://www.nytimes.com/2015/12/10/business/senators-condemn-big-price-increases-for-drugs.html</a> (viewed November 24, 2021).	p. 246
“An Endo International Company,” Par Pharmaceutical, <a href="https://www.parsterileproducts.com/">https://www.parsterileproducts.com/</a> (viewed December 2, 2020).	p. 249
“US9744209B2,” Google Patents, <a href="https://patents.google.com/patent/US9744209B2/en?q=US9744209B2">https://patents.google.com/patent/US9744209B2/en?q=US9744209B2</a> (viewed November 23, 2021).	P .252
“US9750785B2,” Google Patents, <a href="https://patents.google.com/patent/US9750785B2?q=US9750785B2">https://patents.google.com/patent/US9750785B2?q=US9750785B2</a> (viewed November 23, 2021).	p. 320
“Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP),” PR Newswire, <a href="https://www.prnewswire.com/news-releases/par-pharmaceutical-announces-first-fda-approval-of-vasostrict-vasopressin-injection-usp-282391581.html">https://www.prnewswire.com/news-releases/par-pharmaceutical-announces-first-fda-approval-of-vasostrict-vasopressin-injection-usp-282391581.html</a> (viewed December 2, 2020).	p. 385
“Par Pharmaceutical to Acquire JHP Pharmaceuticals,” PR Newswire, <a href="https://www.prnewswire.com/news-releases/par-pharmaceutical-to-">https://www.prnewswire.com/news-releases/par-pharmaceutical-to-</a>	p. 388

<b>Description</b>	<b><u>Page No.</u></b>
acquire-jhp-pharmaceuticals-241264801.html (viewed December 2, 2020).	
“Endo Announces Issuance of Vasostrict® Patent,” PR Newswire, <a href="https://www.prnewswire.com/news-releases/endo-announces-issuance-of-vasostrict-patent-300291415.html">https://www.prnewswire.com/news-releases/endo-announces-issuance-of-vasostrict-patent-300291415.html</a> (viewed December 6, 2020).	p. 392
“Drugmaker Endo settles opioid claims by New York, counties for \$50 mln,” Reuters, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-endo-settles-opioid-claims-by-new-york-counties-50-mln-2021-09-10/">https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-endo-settles-opioid-claims-by-new-york-counties-50-mln-2021-09-10/</a> (viewed November 24, 2021).	p. 395
“A Guide to Crash Carts: Must-Have Features and Medications,” Scott-Clark Medical, <a href="https://www.scott-clark.com/blog/a-guide-to-crash-carts-must-have-features-and-medications/">https://www.scott-clark.com/blog/a-guide-to-crash-carts-must-have-features-and-medications/</a> (viewed November 23, 2021).	p. 399
“Eagle Pharmaceuticals' Vasopressin ANDA Accepted for Filing by the FDA,” Eagle Pharmaceuticals, <a href="https://www.sec.gov/Archives/edgar/data/827871/000110465918024064/a18-10132_1ex99d1.htm">https://www.sec.gov/Archives/edgar/data/827871/000110465918024064/a18-10132_1ex99d1.htm</a> (viewed November 24, 2021).	p. 405
“Par Pharmaceutical Companies Our History,” Par Pharmaceutical, <a href="https://web.archive.org/web/20150321031532/http://www.parpharm.com/index.php?option=com_content&amp;view=article&amp;id=75&amp;Itemid=92">https://web.archive.org/web/20150321031532/http://www.parpharm.com/index.php?option=com_content&amp;view=article&amp;id=75&amp;Itemid=92</a> (viewed December 2, 2020).	p. 408
“Understanding Low Blood Pressure -- the Basics,” WebMD, <a href="https://www.webmd.com/heart/understanding-low-blood-pressure-basics#1">https://www.webmd.com/heart/understanding-low-blood-pressure-basics#1</a> (viewed December 3, 2020).	p. 411
<b>Other</b>	<b>Vol. 7</b>
JHP Pharmaceuticals letter to Dr. Parks and Stockbridge re Pre NDA Meeting Package (September 16, 2011)	p. 1
<b>Internal Par Native Files * Produced in Native Format</b>	<b>Vol. 8</b>
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

Description	<u>Page No.</u>
	
	
<b>Other Native Files * Produced in Native Format.</b>	<b>Vol. 9</b>
Bloomberg Request Builder	*
Symphony Data, pulled September 16, 2021.	*
Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations	*